---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005319"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:20:10.143370+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)

## Summary
- Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).
- Oncology clinical tests (ex-Shield) Q4 57,300 (+24%); full year 206,700 (+20%).
- Biopharma tests Q4 11,050 (+16%); full year 40,500 (+35%).
- Shield screening tests Q4 6,400 with ~$4M revenue in first full commercial quarter.
- Free cash flow -$84M in Q4, -$275M full year; cash & securities $944M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001193125-25-005319
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000119312525005319/0001193125-25-005319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000119312525005319/d890861d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005319
- JSON: https://secwatch.observer/filing/0001193125-25-005319.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.